Biosimilars In EU Seeing Reduced Clinical Data Requirements
This article was originally published in PharmAsia News
After a 'slightly conservative approach' at the beginning, 'we are now getting to the meat of what we can do with biosimilars,' the European Medicine Association's Head of Quality Peter Richardson says.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.